Petosemtamab (FUT8-KO)

Petosemtamab (FUT8-KO) is a knockout version of petosemtamab for the fucosyltransferase 8 gene (FUT8). Petosemtamab (HY-P99406) is an anti-EGFR (Kd: 0.22 nM) and anti-LGR5 (Kd: 0.86 nM) monoclonal antibody (mAb). Petosemtamab leads to blockade of EGFR signaling and receptor degradation in LGR5+ cancer cells. Petosemtamab can be used in the study of solid tumors such as head and neck squamous cell carcinoma (HNSCC), metastatic colorectal cancer (CRC), etc[1][2].

[1]Hollebecque A, et al. Abstract P185: Preliminary antitumor activity of MCLA-158, an IgG1 bispecific antibody targeting EGFR and LGR5, in advanced head and neck squamous cell carcinoma[J]. Molecular Cancer Therapeutics, 2021, 20(12_Supplement): P185-P185.|[2]Argiles G. Phase I dose escalation study of MCLA-158, a first in class bispecific antibody targeting EGFR and LGR5, in metastatic colorectal cancer (CRC)[J]. chemotherapy, 2021, 33: 100.